Drug Trial Radar · NCT05739123
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
728
Planned (sponsor's estimate)
Start
May 8, 2023
Primary completion
May 2033
Study completion May 2033
Sponsor
- Lead sponsor
- Sumitomo Pharma Switzerland GmbHIndustry
- Sponsor type
- Industry
- First posted
- Feb 22, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
Conditions
- Pregnancy Related
- Pregnancy Complications
- Pregnancy, High Risk
Interventions
Relugolix-Containing ProductDrug
Any relugolix-containing therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Congenital Malformation (MCM)Time frame: Up to 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD
Wilmington, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.